[Federal Register Volume 59, Number 9 (Thursday, January 13, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-849]
[[Page Unknown]]
[Federal Register: January 13, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Opportunity for a License for Nonpatented Material
AGENCY: Centers for Disease Control and Prevention (CDC), Public Health
Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), National
Center for Infectious Diseases (NCID), Division of Viral and
Rickettsial Diseases (DVRD), Hepatitis Branch, has available for
licensing recombinant proteins and synthetic peptides containing
broadly immunoreactive antigenic epitopes to be used as
immunodiagnostic reagents for the detection of antibodies to the
Hepatitis C Virus (HCV).
FOR FURTHER INFORMATION CONTACT: If you are interested in the
opportunity for a license to the nonpatented material described above,
please contact the following for additional information.
Technical Contact: Howard A. Fields, Ph.D., Division of Viral and
Rickettsial Diseases, Centers for Disease Control and Prevention (CDC),
1600 Clifton Road, NE., Mailstop A-33, Atlanta, GA 30333, telephone
404-639-2335.
Business Contact: Lisa Blake-Dispigna, Technology Transfer
Representative, National Center for Infectious Diseases, Centers for
Disease Control and Prevention (CDC), 1600 Clifton Road, NE., Mailstop
C-19, Atlanta, GA 30333, telephone 404-639-3227.
SUPPLEMENTARY INFORMATION: A set of recombinant glutathione-S-
transferase fusion proteins have been prepared by using polymerase
chain reaction to amplify the NS3-NS4-NS5 region of the hepatitis C
virus (HCV) genome in 300 (monomers) and 600 (dimers) nucleotide
fragments. Most of the monomers and dimers have been expressed in
Escherichia coli and tested against a panel of anti-HCV positive and
negative sera to ascertain specificity. A full length authentic
fusionless recombinant nucleocapsid protein has also been prepared and
tested as an immunodiagnostic reagent. This single protein alone will
detect approximately 90% of anti-HCV positive sera. Synthetic peptides
have been prepared to the nucleocapsid region in addition to the NS3-
NS4-NS5 region. All the synthetic peptides have been tested to
determine their immunoreactivity.
The nonpatented recombinant proteins and synthetic peptides are now
available for licensing, and if interested, see FOR FURTHER INFORMATION
CONTACT section of notice.
Dated: January 6, 1994.
Ladene H. Newton,
Acting Associate Director for Management and Operations, Centers for
Disease Control and Prevention (CDC).
[FR Doc. 94-849 Filed 1-12-94; 8:45 am]
BILLING CODE 4160-18-P
